



Ref: Syn/CS/SE/BM/2026-27/Apr/07

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 9191
CIN: L85110KA1993PLC014937
www.syngeneintl.com

April 29, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Intimation under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby inform you that, based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors at its meeting held today (i.e. Wednesday, April 29, 2026) have inter-alia considered and approved the following, subject to the approval of the shareholders:

- appointment of Mr. Vijaya Chandru (DIN: 00914988) as an Additional Director (Independent, Non-Executive) w.e.f the 33rd Annual General Meeting, till the conclusion of the Annual General Meeting to be held in 2029.
- appointment of Mr. Arun Chandavarkar (DIN: 01596180) as an Additional Director (Independent, Non-Executive) w.e.f the 33rd Annual General Meeting, till the conclusion of the Annual General Meeting to be held in 2029.
- reappointment of Ms. Vinita Bali (DIN: 00032940), as Additional Non-Executive Director for a further period of one year from July 22, 2026, to July 21, 2027

In accordance with SEBI letter dated June 14, 2018 read along with NSE Circular dated June 20, 2018, having ref no. as - NSE/CML/2018/24, we hereby confirm that Mr. Vijaya Chandru, Mr. Arun Chandavarkar and Ms. Vinita Bali are not debarred from holding the office of director by virtue of any order of SEBI or any other authority.

The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure A**.



The above information will also be available on the website of the Company at www.syngeneintl.com.

Thanking You

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Chethan Yogesh
Company Secretary & Compliance Officer

Encl: as above

Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

i. Mr. Vijaya Chandru

Sr. No.	Particulars	Details
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)-	Appointment as Additional Director (Independent, Non-Executive)
2.	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/re-appointment;	3 years from the conclusion of the 33 rd Annual General Meeting to be held on July 29, 2026
3.	Brief profile	<p>Vijaya Chandru is a leading academic-entrepreneur who has advanced deep-tech innovation in India for over 25 years. Trained in decision sciences (AI) with a PhD in Operations Research from Massachusetts Institute of Technology, his work spans optimization, geometry, logic, and computational biology.</p> <p>He co-founded Strand Life Sciences (2000), PicoPeta Simputers (2001), Yantri Labs Inc. (2018), and CRISPRBITS. He serves on the faculty at National Centre for Biological Sciences, Indian Institute of Science, and Harvard T.H. Chan School of Public Health, and has held tenured positions at Purdue University and IISc.</p> <p>In 2024, American Association for the Advancement of Science elected him Fellow for contributions to theoretical computer science, computational biology, and technology for social good. He was also named a Technology Pioneer by the World Economic Forum in 2006. Chandru leads the “No Disease Orphan by 2030” mission and co-chaired the technology workstream of the The Lancet Commission on Citizen-Centred Health Systems for India.</p>
4.	Disclosure of relationships between directors (in case of appointment)	Not Applicable

ii. Mr. Arun Chandavarkar

Sr. No.	Particulars	Details
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)-	Appointment as Additional Director (Independent, Non-Executive)
2.	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/re-appointment;	3 years from the conclusion of the 33 rd Annual General Meeting to be held on July 29, 2026
3.	Brief profile	<p>Arun Chandavarkar retired as CEO & Joint Managing Director of Biocon Limited on 30 November 2019 after a 29-year career. During his tenure, Chandavarkar was instrumental in transforming Biocon from an enzymes business into a globally recognized biopharma company. He contributed to its 2004 IPO and led key initiatives including biologics partnerships, major R&D and infrastructure investments, divestment of the enzymes business, and organizational restructuring to support growth.</p> <p>He holds a B.Tech. in Chemical Engineering from Indian Institute of Technology Bombay and a PhD in Chemical Engineering from Massachusetts Institute of Technology. He is a former Chairperson of the biotechnology committee at Confederation of Indian Industry and serves as a non-executive director at Biocon Biologics and an independent director at Mynvax Private Limited.</p>
4.	Disclosure of relationships between directors (in case of appointment)	Not Applicable

iii. Ms. Vinita Bali

Sr. No.	Particulars	Details
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)	Appointment as Additional Director (Non-Executive category)
2.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment ;	Appointed from July 22, 2026 till July 21, 2027 (one year)
3.	Brief profile	Ms. Bali is a global business leader with extensive experience in leading and transforming large companies both in India and overseas. She served as Chief Executive Officer & MD of Britannia Industries Ltd., from 2005 to 2014. Prior to that, she worked for The Coca-Cola Company and Cadbury Schweppes Plc in a variety of Marketing, General Management and Chief Executive roles in the UK, Nigeria, South Africa, USA and Chile. At present, she is a Non-Executive Director on the global boards of SATS Ltd and Cognizant Technology Solutions, and in India, she serves on the board of Bajaj Auto Limited. At Syngene, she is a member of the Nomination & Remuneration Committee, Audit Committee and the Corporate Social Responsibility Committee.
4.	Disclosure of relationships between directors (in case of appointment)	Not Applicable